Genetic toxicology in the 21st century: Reflections and future directions

Environmental and Molecular Mutagenesis

Volumn 52, Issue 5, 2011, Pages 339-354

  Mahadevan, Brinda ^a   Snyder, Ronald D ^a   Waters, Michael D ^b   Benz, R Daniel ^c   Kemper, Raymond A ^d   Tice, Raymond R ^e   Richard, Ann M ^f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b INTEGRATED LABORATORY SYSTEMS   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^f U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Genotoxicity; High throughput screening; Mutagenicity; Toxicogenomics

Indexed keywords

ENVIRONMENTAL CHEMICAL; INDUSTRIAL CHEMICAL;

BIOASSAY; CARCINOGENESIS; CARCINOGENICITY; COMPUTER MODEL; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; GENETIC TOXICOLOGY; GENOTOXICITY; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR MODEL; MUTAGENICITY; NONHUMAN; REVIEW; UNITED STATES;

ENVIRONMENTAL MONITORING; MODELS, THEORETICAL; TOXICOGENETICS; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

ANIMALIA;

EID: 79957884917     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20653     Document Type: Review

References (81)

1. Ashby J. 1985. Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity. Environ Mutagen 7: 919-921.
2. Auerbach SS, Shah RR, Mav D, Smith CS, Walker NJ, Vallant MJ, Boorman GA, Irwin RD. 2010. Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. Toxicol Appl Pharmacol 243: 300-314.
3. Bentzien J, Hickey ER, Kemper RA, Brewer ML, Dyekjaer JD, East SP, Whittaker M. 2010. An in silico method for predicting Ames activities of primary aromatic amines by calculating the stabilities of nitrenium ions. J Chem Inf Model 50: 274-297.
4. Benz RD. 2007. Toxicological and clinical computational analysis and the U.S. FDA/CDER. Expert Opin Drug Metab Toxicol 3: 109-124.
5. Bucher J, Portier C. 2004. Human carcinogenic risk evaluation, part V: The national toxicology program vision for assessing the human carcinogenic hazard of chemicals. Toxicol Sci 82: 363-366.
6. Buerstedde JM, Takeda S. 1991. Increased ratio of targeted to random integration after transfection of chicken B cell lines. Cell 67: 179-188.
7. Claxton LD, Umbuzeiro GA, DeMarini DM. 2010. The Salmonella mutagenicity assay: The stethoscope of genetic toxicology for the 21st century. Environ Health Perspect 118: 1515-1522.
8. Collins FS, Gray GM, Bucher JR. 2008. Toxicology. Transforming environmental health protection. Science 319: 906-907.
9. Contrera JF, Matthews EJ, Benz RD. 2003. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and e-state indices. Reg Toxicol Pharmacol 38: 243-259.
10. Contrera JF, MacLaughlin P, Hall LH, Kier LB. 2005a. QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr Drug Discov Technol 2: 55-67.
11. Contrera JF, Matthews EJ, Kruhlak NL, Benz RD. 2005b. In silico screening of chemicals for bacterial mutagenicity using electrotopological e-state indices and MDL QSAR software. Reg Toxicol Pharmacol 43: 313-323.
12. Contrera JF, Kruhlak NL, Matthews EJ, Benz RD. 2007. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. Reg Toxicol Pharmacol 49: 172-182.
13. Contrera JF, Matthews EJ, Kruhlak NL, Benz RD. 2008. In silico screening of chemicals for genetic toxicity using MDL-QSAR, nonparametric discriminant analysis, e-state, connectivity, and molecular property descriptors. Toxicol Mech Meth 18: 207-216.
14. DeMarini DM. 2000. Influence of DNA repair on mutation spectra in Salmonella. Mutat Res 450: 5-17.
15. Dix DJ, Houck KA, Martin MT, Richard AM, Setzer RW, Kavlock RJ. 2007. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci 95: 5-12.
16. Eastmond DA, Hartwig A, Anderson D, Anwar WA, Cimino MC, Dobrev I, Douglas GR, Nohmi T, Phillips DH, Vickers C. 2009. Mutagenicity testing for chemical risk assessment: Update of the WHO/IPCS harmonized scheme. Mutagenesis 24: 341-349.
17. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. 2005. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res 575: 61-84.
18. Ellinger-Ziegelbauer H, Gmuender H, Bandenburg A, Ahr HJ. 2008. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat Res 637: 23-39.
19. Ellinger-Ziegelbauer H, Aubrecht J, Kleinjans JC, Ahr HJ. 2009a. Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity. Toxicol Lett 186: 36-44.
20. Ellinger-Ziegelbauer H, Fostel JM, Aruga C, Bauer D, Boitier E, Deng S, Dickinson D, Le Fevre AC, Fornace AJJr, Grenet O, Gu Y, Hoflack JC, Shiiyama M, Smith R, Snyder RD, Spire C, Tanaka G, Aubrecht J. 2009b. Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms. Toxicol Sci 110: 341-352.
21. European Medicines Agency, Committee for the Evaluation of Medicinal Products. 1997. Replacement of animal studies by In vitro models. Available at: Accessed 17 March, 2011.
22. European Medicines Agency, Committee for Medicinal Products for Human Use. 2006. Guideline on the limits of genotoxic impurities. EMEA/CHMP/QWP/251344/2006. Available at: Accessed 15 March, 2011.
23. Fielden MR, Brennan R, Gollub J. 2007. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci 99: 90-100.
24. Fielden MR, Nie A, McMillian M, Elangbam CS, Trela BA, Yang Y, Dunn RT, Dragan Y, Fransson-Stehen R, Bogdanffy M. 2008. Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. Toxicol Sci 103: 28-34.
25. Ford GP, Griffin GR. 1992. Relative stabilities of nitrenium ions derived from heterocyclic amine food carcinogens: Relationship to mutagenicity. Chem Biol Interact 81: 19-33.
26. Fung VA, Barrett JC, Huff J. 1995. The carcinogenesis bioassay in perspective: Application in identifying human cancer hazards. Environ Health Perspect 103: 680-683.
27. Summary by Chemical of Carcinogenicity Results in the Carcinogen Potency Data Base (CPDB). Technical Reports of the NCI/NTP. Available at: Accessed 17 March, 2011.
28. Gold LS, Manley NB, Slone TH, Rohrbach L, Garfinkel GB. 2005. Supplement to the Carcinogenic Potency Database (CPDB): Results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. Toxicol Sci 85: 747-808.
29. Hendry LB, Chu CK, Rosser ML, Copeland JA, Wood JC, Mahesh VB. 1994. Design of novel antiestrogens. J Steroid Biochem Mol Biol 49: 269-280.
30. Hori T, Amano M, Suzuki A, Backer CB, Welburn JP, Dong Y, McEwen BF, Shang WH, Suzuki E, Okawa K, Cheeseman IM, Fukagawa T. 2008. CCAN makes multiple contacts with centromeric DNA to provide distinct pathways to the outer kinetochore. Cell 135: 1039-1052.
31. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, Zheng W, Austin CP. 2006. Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 103: 11473-11478.
32. Ji K, Kogame T, Choi K, Wang X, Lee J, Taniguchi Y, Takeda S. 2009. A novel approach using DNA-repair-deficient chicken DT40 cell lines for screening and characterizing the genotoxicity of environmental contaminants. Environ Health Perspect 117: 1737-1744.
33. Judson RS, Richard AM, Dix DJ, Houck K, Martin MT, Kavlock RJ, Dellarco V, Henry T, Holderman T, Sayre P, Tan S, Carpenter T, Smith E. 2009. The toxicity data landscape for environmental chemicals. Environ Health Perspect 117: 685-695.
34. Judson RS, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, Mortensen HM, Reif DM, Rotroff DM, Shah I, Richard AM, Dix DJ. 2010. In Vitro screening of environmental chemicals for targeted testing prioritization: The ToxCast project. Environ Health Perspect 118: 485-492.
35. Kazius J, McGuire R, Bursi R. 2005. Derivation and validation of toxicophores for mutagenicity prediction. J Med Chem 48: 312-320.
36. Kavlock RJ, Austin CP, Tice RR. 2009. Toxicity testing in the 21st century: Implications for human health risk assessment. Risk Anal 29: 485-487.
37. Kirkland D, Speit G. 2008. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing in vivo. Mutat Res 654: 114-132.
38. Kirkland D, Aardema M, Henderson L, Muller L. 2005. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res 584: 1-256.
39. Kirkland D, Aardema M, Muller L, Makoto H. 2006. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. Mutat Res 608: 29-42.
40. Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R, Darroudi F, Elhajouji A, Glatt H, Hastwell P, Hayashi M, Kasper P, Kirchner S, Lynch A, Marzin D, Maurici D, Meunier JR, Müller L, Nohynek G, Parry J, Parry E, Thybaud V, Tice R, van Benthem J, Vanparys P, White P. 2007. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM workshop. Mutat Res 628: 31-55.
41. Knight AW, Little S, Houck K, Dix D, Judson R, Richard A, McCarroll N, Ackerman G. 2009. Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast chemicals. Reg Toxicol Pharmacol 55: 188-199.
42. Knudsen TB, Martin MT, Kavlock RJ, Judson RJ, Dix DJ, Singh AV. 2009. Profiling the activity of environmental chemicals in prenatal developmental toxicity studies using the U.S. EPA's ToxRefDB. Reproduct Toxicol 28: 209-219.
43. Kruhlak NL, Contrera JF, Benz RD, Matthews EJ. 2007. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. Adv Drug Deliv Rev 59: 43-55.
44. Martin MT, Judson RS, Reif DM, Kavlock RJ, Dix DJ. 2009a. Profiling chemicals based on chronic toxicity results from the U.S. EPA ToxRef Database. Environ Health Perspect 117: 392-399.
45. Martin MT, Mendez E, Corum DG, Judson RS, Kavlock RJ, Rotroff DM, Dix D. 2009b. Profiling the reproductive toxicity of chemicals from multigeneration studies in the Toxicity Reference Database (ToxRefDB). Toxicol Sci 110: 181-190.
46. Martin MT, Dix DJ, Judson R, Kavlock RJ, Reif D, Richard AM, Rotroff D, Romanov D, Romanov S, Medvedev A, Poltoratskaya N, Gambarian M, Moeser M, Makarov SS, Houck KA. 2010. Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. Chem Res Toxicol 23: 578-590.
47. Matthews EJ, Contrera JF. 1998. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES Software. Reg Toxicol Pharmacol 28: 242-264.
48. Matthews EJ, Benz RD, Contrera JF. 2000. Use of toxicological information in drug design. J Molec Graphics Model 18: 605-614.
49. Matthews EJ, Kruhlak NL, Cimino MC, Benz RD, Contrera JF. 2006a. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints. Reg Toxicol Pharmacol 44: 83-96.
50. Matthews EJ, Kruhlak NL, Cimino MC, Benz RD, Contrera JF. 2006b. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. Reg Toxicol Pharmacol 44: 97-110.
51. Matthews EJ, Kruhlak NL, Benz RD, Contrera JF, Marchant CA, Yang C. 2008. Combined use of MC4PC, MDL-QSAR, Leadscope PDM, and Derek for Windows Software to achieve high-performance, high-confidence, mode of action-based predictions of chemical carcinogenesis in rodents. Toxicol Mech Meth 18: 189-206.
52. McCann J, Ames BN. 1976. Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals: discussion. Proc Nat Acad Sci USA 73: 950-954.
53. McCann J, Choi E, Yamasaki E, Ames BN. 1975. Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals: Discussion. Proc Nat Acad Sci USA 72: 5135-5139.
54. National Research Council (NRC). 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC: National Academies Press.
55. Nakayama K, Kawano Y, Kawakami Y, Moriwaki N, Sekijima M, Otsuka M, Yakabe Y, Miyaura H, Saito K, Sumida K, Shirai T. 2006. Differences in gene expression profiles in the liver between carcinogenic and non-carcinogenic isomers of compounds given to rats in a 28-day repeat-dose toxicity study. Toxicol Appl Pharmacol 217: 299-307.
56. Nie AY, McMillian M, Parker JB, Leone A, Bryant S, Yieh L, Bittner A, Nelson J, Carmen A, Wan J, Lord PG. 2006. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog 45: 914-33.
57. Richard A, Yang C, Judson R. 2008. Toxicity data informatics: Supporting a new paradigm for toxicity prediction. Tox Mech Meth 18: 103-118.
58. Snyder RD. 2000. The use of catalytic topoisomerase inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells. Environ Mol Mutagen 35: 13-21.
59. Snyder RD. 2007. Assessment of atypical DNA intercalating agents in biological and in silico systems. Mutat Res 623: 72-82.
60. Snyder RD. 2009. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity. Environ Mol Mutagen 50: 435-450.
61. Snyder RD, Arnone M. 2002. Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. Mutat Res 503: 21-35.
62. Snyder RD, Strekowski L. 1999. Enhancement of bleomycin-induced micronucleus formation in V79 cells as a rapid and sensitive screen for non-covalent DNA binding compounds. Mutat Res 444: 181-192.
63. Snyder RD, Ewing DE, Hendry LB. 2004. Evaluation of DNA intercalation potential of pharmaceuticals and other chemicals by cell-based and three-dimensional computational approaches. Environ Mol Mutagen 44: 163-173.
64. Snyder RD, Ewing DE, Hendry LB. 2006. DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutat Res 609: 47-59.
65. Thomas RS, Pluta L, Yang L, Halsey TA. 2007. Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays. Toxicol Sci 97: 55-64.
66. Tsujimura K, Asamoto M, Suzuki S, Hokaiwado N, Ogawa K, Shirai T. 2006. Prediction of carcinogenic potential by a toxicogenomic approach using rat hepatoma cells. Cancer Sci 97: 1002-1010.
67. U.S. EPA. 2011a. EPA ToxCast. Available at: Accessed 15 January, 2011.
68. U.S. EPA. 2011b. ToxRefDB. Available at: Accessed 15 January, 2011.
69. U.S. EPA. 2011c. DSSTox. Available at: Accessed 15 January, 2011.
70. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2008. Guidance for industry-safety testing of drug metabolites. Available at: Accessed 17 March, 2011.
71. Van Delft JH, Van Agen E, Van Breda SG, Herwijnen MH, Staal YC, Kleinjans JC. 2004. Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling. Carcinogenesis 25: 1265-1276.
72. Van Delft JH, Van Agen E, van Breda SG, Herwijnen MH, Staal YC, Kleinjans JC. 2005. Comparison of supervised clustering methods to discriminate genotoxic from non-genotoxic carcinogens by gene expression profiling. Mutat Res 575: 17-33.
73. Waters MD, Auletta A. 1981. The GENE-TOX program: genetic activity evaluation. J Chem Inf Comput Sci 21: 35-38.
74. Waters MD, Stack HF, Jackson MA, Bridges BA, Adler I-D. 1994. The performance of short-term tests in identifying potential germ cell mutagens. A qualitative and quantitative analysis. Mutat Res 341: 109-131.
75. Waters MD, Stack HF, Jackson MA. 1999. Genetic toxicology data in the evaluation of potential human environmental carcinogens. Mutat Res 437: 21-49.
76. Waters MD, Jackson MA, Lea IA. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. Mutat Res 705: 184-200.
77. Xia M, Huang R, Witt KL, Southall N, Fostel J, Cho M-H, Jadhav A, Smith CS, Inglese J, Portier CJ, Tice RR, Austin CP. 2008. Compound cytotoxicity profiling using quantitative high-throughput screening. Environ Health Perspect 116: 284-291.
78. Yang C, Arnby CH, Arvidson K, Aveston S, Benigni R, Benz RD, Boyer S, Contrera J, Dierkes P, Han X, Jaworska J, Kemper RA, Kruhlak NL, Matthews EJ, Rathman JF, Richard AM. 2008. Understanding genetic toxicity through data mining: The process of building knowledge by Integrating multiple genetic toxicity databases. Tox Mech Meth 18: 277-295.
79. Zeiger E. 2004. History and rationale of genetic toxicity testing: an impersonal, and sometimes personal, view. Environ Mol Mutagen 44: 363-371.
80. Zeiger E, Margolin BH. 2000. The proportions of mutagens among chemicals in commerce. Reg Toxicol Pharmacol 32: 219-225.
81. Zhao GY, Sonoda E, Barber LJ, Oka H, Murakawa Y, Yamada K, Ikura T, Wang X, Kobayashi M, Yamamoto K. 2007. A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination. Mol Cell 25: 663-675.